We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+19.11%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$25.4M
Cap. Flow
-$18.4M
Cap. Flow %
-9.38%
Top 10 Hldgs %
68.13%
Holding
55
New
16
Increased
5
Reduced
7
Closed
19

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$15.5M
2
GSK icon
GSK
GSK
+$12.8M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.3M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$7.13M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.64M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$14.4M
2
AZN icon
AstraZeneca
AZN
+$8.73M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.09M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.18M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 75.13%
2 Miscellaneous 24.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
26
CALL
Tvardi Therapeutics
TVRD
$22.1M
$1.38M 0.7%
+2,083
New +$1.11M
CLSD
27
DELISTED
Clearside Biomedical
CLSD
$959K 0.49%
8,051
– –
ZSAN
28
DELISTED
Zosano Pharma Corporation
ZSAN
$950K 0.48%
+714
New +$862K
ADXS
29
DELISTED
Advaxis Inc
ADXS
$791K 0.4%
6,453
-6,880
-52% -$893K
VSTM icon
30
Verastem
VSTM
$691M
$696K 0.36%
28,000
– –
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$612K 0.31%
+10,000
New +$581K
ALKS icon
32
Alkermes
ALKS
$7.84B
$550K 0.28%
+9,400
New +$533K
OBSV
33
DELISTED
ObsEva SA Ordinary Shares
OBSV
$521K 0.27%
+50,000
New +$614K
VTGN icon
34
VistaGen Therapeutics
VTGN
$10.4M
$271K 0.14%
4,604
– –
NTBL
35
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$183K 0.09%
952
– –
STDY
36
DELISTED
SteadyMed Ltd
STDY
$31K 0.02%
+5,399
New +$18K
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$32.4B
– –
-165,000
Closed -$6.18M
ASND icon
38
Ascendis Pharma A/S
ASND
$15.7B
– –
-100,000
Closed -$2.02M
AZN icon
39
AstraZeneca
AZN
$257B
– –
-150,000
Closed -$8.73M
KYNB
40
Kyntra Bio
KYNB
$29.3M
– –
-4,640
Closed -$2.48M
FOLD
41
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-100,000
Closed -$497K
INDP icon
42
Indaptus Therapeutics
INDP
$493M
– –
-62
Closed -$791K
INSM icon
43
Insmed
INSM
$26.9B
– –
-322,044
Closed -$4.26M
NBIX icon
44
Neurocrine Biosciences
NBIX
$15.4B
– –
-120,000
Closed -$4.64M
NVS icon
45
Novartis
NVS
$267B
– –
-220,968
Closed -$14.4M
RDHL
46
Redhill Biopharma
RDHL
$3.55M
– –
-95
Closed -$994K
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-503,000
Closed -$1.53M
TCON
48
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-64
Closed -$62K
TRVN
49
DELISTED
Trevena, Inc.
TRVN
– –
-638
Closed -$2.35M
CNCE
50
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-167,866
Closed -$1.73M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Nexthera Capital held 55 positions worth $196M, up 15% from $171M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Nexthera Capital withdrew a net $18.4M in Q1 2017, closing 19 positions and reducing 7 holdings. Its most notable exit was Novartis, an estimated $14.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

Against the trend, Nexthera Capital opened a new position in GSK worth $13.3M.

  • Nexthera Capital's largest Q1 2017 buy was GSK: 253,200 shares worth $13.3M.
  • Nexthera Capital added most to Pfizer in Q1 2017, an estimated $15.5M increase.
  • Nexthera Capital's biggest Q1 2017 reduction was Shire pic, cutting an estimated $4.54M.
  • Nexthera Capital fully exited Novartis in Q1 2017, selling an estimated $14.4M.
  • Nexthera Capital's ten largest holdings make up 68% of its $196M portfolio in Q1 2017.
  • Nexthera Capital opened 16 new positions and closed 19 in Q1 2017.
  • Nexthera Capital's portfolio value rose 15% quarter-over-quarter to $196M.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.